What is Ensoma?
Ensoma is a biotechnology firm at the forefront of genetic medicine, specializing in in vivo gene editing. By targeting hematopoietic stem cells directly inside the body, the company aims to bypass the limitations of traditional ex vivo therapies, which often require complex and costly manufacturing processes. This innovative methodology is designed to deliver curative, single-dose treatments for a wide array of genetic conditions, positioning Ensoma as a critical player in the future of precision medicine and regenerative therapy.
How much funding has Ensoma raised?
Ensoma has raised a total of $258M across 3 funding rounds:
Series A
$70M
Series B
$135M
Other Financing Round
$53M
Series A (2021): $70M with participation from 5AM Ventures, Viking Global Investors, Takeda Ventures, and F-Prime Capital
Series B (2023): $135M led by Qatar Investment Authority, Arix Bioscience, Kite, Mirae Asset Financial Group, Bill & Melinda Gates Foundation, F-Prime Capital Partners, 5AM Ventures, Solasta Ventures, SymBiosis, Delos Capital, and Catalio Capital Management
Other Financing Round (2025): $53M supported by Delos Capital, Solasta Ventures, 5AM Ventures, Hanwha Impact Partners, F-Prime Capital, RTW Investments, Viking Global Investors, Gilead Sciences, Catalio Capital Management, and SymBiosis
Key Investors in Ensoma
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
What's next for Ensoma?
With the latest capital infusion, Ensoma is well-positioned to accelerate its clinical development pipeline and scale its manufacturing capabilities. The strategic focus will likely remain on validating its in vivo platform through human proof-of-concept studies while expanding its therapeutic reach. As the company transitions from a research-heavy organization to a clinical-stage powerhouse, the continued backing from institutional investors will be instrumental in navigating the regulatory landscape and bringing transformative genetic medicines to patients globally.
See full Ensoma company page
